PlainRecalls
FDA Drug Moderate Class II Ongoing

R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use. THIS IS A COMPOUNDED DRUG. QuVA Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, TX 77478. NDC 70092-1433-50

Reported: November 5, 2025 Initiated: October 10, 2025 #D-0113-2026

Product Description

R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use. THIS IS A COMPOUNDED DRUG. QuVA Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, TX 77478. NDC 70092-1433-50

Reason for Recall

Presence of Particulate Matter

Details

Recalling Firm
QuVa Pharma, Inc.
Units Affected
75,885 syringes
Distribution
U.S. Nationwide
Location
Sugar Land, TX

Frequently Asked Questions

What product was recalled?
R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use. THIS IS A COMPOUNDED DRUG. QuVA Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, TX 77478. NDC 70092-1433-50. Recalled by QuVa Pharma, Inc.. Units affected: 75,885 syringes.
Why was this product recalled?
Presence of Particulate Matter
Which agency issued this recall?
This recall was issued by the FDA Drug on November 5, 2025. Severity: Moderate. Recall number: D-0113-2026.